CSL broadens anti-rejection portfolio

Biotechnology group CSL has bought Vitaeris Inc, a clinical-stage biotechnology company commercialising a treatment for rejection in solid organ kidney transplant patients. The Vancouver, Canada based company has been in partnership with CSL since 2017 developing clazakizumab, an anti-interleukin-6 (IL-6) monoclonal antibody (MAB), for the potential treatment of chronic active antibody-mediated rejection (AMR), the leading…

K-Tig to work with Bisalloy and Axiom Precision in defence

Welding technology developer K-TIG is to work with Bisalloy Steels and Axiom Precision Manufacturing to develop specialist welding capabilities for the defence sector. The three companies have signed a memorandum of understanding to jointly develop a sovereign capability in the efficient and effective welding of specialist steels. Their target is to maximise Australian participation in…